Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 36.09% is 146% above its 1-year average of 14.68%, near the high end of its 1-year range (0.66%–36.09%).
As of the fiscal period ended Tuesday, June 30, 2026. 145.84% above its 12-month average of 14.68%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 36.09%.
DEBT TO ASSETS RATIO
36.09%
DEBT TO ASSETS RATIO AVG TTM
14.68%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+145.84%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+39999.43%
vs the sector median at left
Turn Therapeutics Inc.
Market Cap
$346.73M
Debt to Assets Ratio
36.09%
TTM Avg
14.68%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$344.04M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$349.70M
Debt to Assets Ratio
0.61%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$353.88M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$355.36M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$355.43M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$359.53M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | $346.73M | 36.09% | 14.68% | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | 0.00% | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | 0.61% | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $352.67M | 0.71% | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $353.00M | 1.19% | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | 0.19% | N/A | N/A | N/A |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 0.06% | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | 0.03% | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | 0.00% | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | 0.38% | N/A | N/A | N/A |
Debt/Assets
36.1%
Debt/Equity
8.91
Current Ratio
1.19
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 36.09% |
| 2026-03-31 | 32.21% |
| 2025-12-31 | 0.66% |
| 2025-09-30 | 2.10% |
| 2025-06-30 | 2.34% |
